Comparisons › ABBV / LLY
AbbVie vs Eli Lilly: comparing ABBV and LLY stock
12-month growth, from 100━ ABBV +35.2% ━ LLY +48.1%
| Metric | ABBV | LLY |
|---|---|---|
| Price, $ | 288.24 | 1,364.73 |
| Year to date | +28.2% ● | +27.4% |
| 12 months | +35.2% | +48.1% ● |
| From 52-week high | −4.8% ● | −6.1% |
| vs 200-day average | +21.1% | +24.3% ● |
| P/E | 22.5 | 42.7 |
| Dividend yield | 2.47% ● | 0.49% |
| Revenue growth, YoY | +10.7% | +45.5% ● |
| Operating income growth | +18.8% | +70.2% ● |
| Operating margin | 36.6% | 51.2% ● |
| Gross margin | 73.7% | 83.6% ● |
| Market cap | $509.5B | $1.28T |
| Next earnings | Feb 3, 2027 | Feb 10, 2027 |
● — whose figure is higher, not which is better. Data as of Nov 5, 2026.
Ratings and a detailed chart for each are in the terminal.
Open the terminalFAQ
Which is better to buy: AbbVie or Eli Lilly?
We do not advise what to buy. By the numbers: Eli Lilly rose more over the year (+48.1%); AbbVie is closer to its 52-week high; Eli Lilly has the higher operating margin; Eli Lilly is growing revenue faster; AbbVie has the lower P/E. How to weigh such signs is covered in «How to analyse a stock».
Can I buy both?
Yes. Many hold several companies in one industry to avoid depending on one. A broad index fund often already holds the largest US companies.
When do they report?
AbbVie — Feb 3, 2027; Eli Lilly — Feb 10, 2027.